Bicycle Therapeutics is developing first in class medicines to treat cancer and other debilitating diseases. Our bicyclic peptides (Bicycles®) are designed to rapidly penetrate the tumour, delivering payloads selectively to where they are needed while minimising exposure to normal tissue and associated toxicities.
Bicycles are a new therapeutic modality combining the attributes of antibodies, small molecules and peptides within one molecule. Bicycles exhibit the affinity and selective pharmacology usually associated with an antibody, the distribution kinetics of a small molecule, allowing rapid extravasation and tumour penetration, and the “tuneable” pharmacokinetic half-life and renal clearance of a peptide, sparing liver and gastrointestinal toxicity often seen with other drug modalities.
Bicycles can be used as standalone therapeutic entities or coupled to deliver a variety of therapeutic payloads, including potent cytotoxins, immune modulators, small molecule NCEs, radionuclides or nucleic acids. Bicycle Therapeutics’ initial focus is on Bicycle Drug Conjugates® (BDCs) that selectively deliver toxins to tumours, killing them with a high degree of precision and minimal effects on healthy cells. BDCs take advantage of Bicycles’ inherent properties of high target affinity and specificity, fast penetration into the tumour and low systemic exposure, combined with rapid excretion of excess toxin via the kidney. BT1718, Bicycle’s lead BDC, has completed GLP toxicology studies and is expected to receive a Clinical Trial Authorization in 2017 in collaboration with Cancer Research UK.
Bicycle Therapeutics is also exploring other uses for its Bicycle platform in oncology and other therapeutic areas, where simple unelaborated Bicycles and Bicycles carrying alternative payloads may have further utility. The company is collaborating in oncology, as evidenced by the recently announced CRUK partnership, and in other areas, such as: respiratory and cardiovascular and metabolic disease with the recently announced AstraZeneca collaboration, to realise the full therapeutic potential of the Bicycle technology.
Bicycle Therapeutics is well-positioned to exploit the promise of its bicyclic peptide technology platform and is supported by top-tier investors. The company is developing its own pipeline of Bicycle molecules as well as seeking research collaborations. This provides a variety of opportunities for candidates seeking to join a dynamic and entrepreneurial biotech company both within its UK operation, based at Cambridge, UK and its newly opened U.S. facility in Cambridge, Massachusetts.